Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP24A1 | Q07973 | 1/20 | 0.38 |
| ▸ | AHR | P35869 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.34 |
| ▸ | TBXAS1 | P24557 | 3/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | EGLN3 | Q9H6Z9 | 1/20 | 0.33 |
| ▸ | CYP17A1 | P05093 | 2/20 | 0.32 |
| ▸ | FAAH | O00519 | 1/20 | 0.32 |
| ▸ | MGLL | Q99685 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1199383 | 0.91 | PRKCA (0.38) | CYP24A1AHRALDH1A1TBXAS1LMNA | |
| SCHEMBL1490570 | 0.85 | CYP24A1 (0.38) | CYP24A1AHRALDH1A1TBXAS1LMNA | |
| SCHEMBL38661546 | 0.84 | CYP24A1 (0.38) | CYP24A1AHRTBXAS1CYP17A1 | |
| SCHEMBL31053780 | 0.84 | CYP24A1 (0.38) | CYP24A1AHRTBXAS1CYP17A1 | |
| SCHEMBL24587752 | 0.83 | TBXAS1 (0.38) | CYP24A1AHRTBXAS1 | |
| SCHEMBL25299195 | 0.82 | TBXAS1 (0.41) | CYP24A1TBXAS1SMN1; SMN2 | |
| SCHEMBL24587767 | 0.82 | TBXAS1 (0.41) | CYP24A1TBXAS1SMN1; SMN2 | |
| SCHEMBL38660965 | 0.82 | TBXAS1 (0.41) | CYP24A1TBXAS1SMN1; SMN2 | |
| SCHEMBL38662147 | 0.82 | TBXAS1 (0.41) | CYP24A1TBXAS1SMN1; SMN2 | |
| SCHEMBL24587006 | 0.82 | TBXAS1 (0.41) | CYP24A1TBXAS1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118574808-A | Ionizable amine lipids and lipid nanoparticles | 比姆医疗股份有限公司 | 2024-08-30 | — | — | CN | disclosed |
| US-20110319396-A1 | BENZODIAZEPIN-2-ON DERIVATIVES | MSD K.K. (JP) | 2011-12-29 | — | — | US | disclosed |
| CN-102282158-A | Azepinone derivatives | — | 2011-12-14 | — | — | CN | disclosed |
| EP-2389366-A1 | BENZODIAZEPIN-2-ON DERIVATIVES | MSD K.K. (JP) | 2011-11-30 | — | — | EP | disclosed |
| US-8040502-B2 | Optical inspection of flat media using direct image technology | WDI WISE DEVICE INC. (CA) | 2011-10-18 | — | — | US | disclosed |
| US-20110212891-A1 | AZEPINONE DERIVATIVES | MSD K.K. | 2011-09-01 | — | — | US | disclosed |
| US-20110212891-A1 | AZEPINONE DERIVATIVES | MSD K.K. | 2011-09-01 | — | — | US | disclosed |
| WO-2010084979-A1 | BENZODIAZEPIN-2-ON DERIVATIVES | BANYU PHARMACEUTICAL CO.,LTD. (JP) | 2010-07-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110212891-A1 | AZEPINONE DERIVATIVES | AZI2, NDUFS3, RPS4Y1 | CYP24A1 1963/4885AHR 2253/4885ALDH1A1 735/4885 |
| US-20110319396-A1 | BENZODIAZEPIN-2-ON DERIVATIVES | DGAT1, DGAT2, GRIN1 | CYP24A1 1576/4885AHR 2733/4885ALDH1A1 1126/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.